64372-56-1

Basic information

• Product Name: Citalopram Related Compound A (25 mg) (1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide)
• Synonyms: Citalopram Related Compound A (25 mg) (1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide);CitalopraM EP IMpurity A;1-[3-(DiMethylaMino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarboxaMide;CitalopraM Related CoMpound A;1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carboxamide;(S)-1-[3-Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3- dihydro-5-isobenzofuran-carbonitrile oxalate (ESCITALOPRAM OXALAT
• CAS NO: 64372-56-1
• Molecular Formula: C₂₀H₂₃FN₂O₂
• Molecular Weight: 342.4072232
• Product Categories: Neurochemicals,Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 64372-56-1.mol
• Article Data: 6

Chemical Properties

• Melting Point: 126-128℃ (ethanol )
• Boiling Point: 444.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.183±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 16.06±0.40(Predicted)
• CAS DataBase Reference: Citalopram Related Compound A (25 mg) (1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide)(CAS DataBase Reference)
• NIST Chemistry Reference: Citalopram Related Compound A (25 mg) (1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide)(64372-56-1)
• EPA Substance Registry System: Citalopram Related Compound A (25 mg) (1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide)(64372-56-1)

Safety Data

• Hazardous Substances Data: 64372-56-1(Hazardous Substances Data)

Usage

Description

Citalopram Related Compound A (25 mg) (1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide) is an impurity of Citalopram, a well-known inhibitor of serotonin (5-HT) uptake. Citalopram Related Compound A (25 mg) (1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide) is utilized in the pharmaceutical industry, specifically for the development and manufacturing of antidepressant medications.

Uses

Used in Pharmaceutical Industry:
Citalopram Related Compound A (25 mg) (1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide) is used as an impurity in the production of Citalopram, an antidepressant medication. It serves as an inhibitor of serotonin (5-HT) uptake, which helps in managing the symptoms of depression and anxiety by increasing the availability of serotonin in the brain. Citalopram Related Compound A (25 mg) (1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide) plays a crucial role in the development and manufacturing process of Citalopram, ensuring the efficacy and safety of the final product.

Upstream product

• 59729-32-7 citalopram hydrobromide 
• 103146-25-4 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile 
• 59729-33-8 1-(3-dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile 

Downstream Products

• 59729-33-8 1-(3-dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile 
• 440121-09-5 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxylic acid 

Relevant articles and documents

Synthesis of novel 5-(aroylhydrazinocarbonyl)escitalopram as cholinesterase inhibitors

A novel series of 5-(aroylhydrazinocarbonyl)escitalopram (58–84) have been designed, synthesized and tested for their inhibitory potential against cholinesterases. 3-Chlorobenzoyl- (71) was found to be the most potent compound of this series having IC50 1.80 ± 0.11 μM for acetylcholinesterase (AChE) inhibition. For the butyrylcholinesterase (BChE) inhibition, 2-bromobenzoyl- (76) was the most active compound of the series with IC50 2.11 ± 0.31 μM. Structure-activity relationship illustrated that mild electron donating groups enhanced enzyme inhibition while electron withdrawing groups reduced the inhibition except o-NO2. However, size and position of the substituents affected enzyme inhibitions.. In docking study of AChE, the ligands 71, 72 and 76 showed the scores of 5874, 5756 and 5666 and ACE of ?64.92,-203.25 and ?140.29 kcal/mol, respectively. In case of BChE, ligands 71, 76 and 81 depicted high scores 6016, 6150 and 5994 with ACE values ?170.91, ?256.84 and ?235.97 kcal/mol, respectively.

Citalopram hydrobromide: Degradation product characterization and a validated stability-indicating LC-UV method

Five degradation products (I-V) of citalopram hydrobromide (CTL) were formed under different forced degradation conditions. Products I and II were formed under hydrolytic conditions while product III-V were formed under photolytic conditions. Products II

Process for the preparation of citalopram hydrobromide

The present invention relates to an industrially advantageous process for the preparation of pure citalopram hydrobromide.